Galectin Therapeutics Announces Positive New Psoriasis and Atopic Dermatitis Clinical Data, Seeking Strategic Partnerships for Therapy of Severe Skin Diseases
November 10, 2016 08:00 ET
|
Galectin Therapeutics
NORCROSS, Ga., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced its plans to...
Galectin Therapeutics Reports Third Quarter 2016 Financial Results and Provides Business Update
November 08, 2016 08:00 ET
|
Galectin Therapeutics
NORCROSS, Ga., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer,...
Galectin Therapeutics to Webcast Corporate Presentation at the MicroCap Conference on October 25 in Philadelphia
October 17, 2016 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., Oct. 17, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...
Galectin Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference
August 31, 2016 08:00 ET
|
Galectin Therapeutics
NORCROSS, Ga., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer,...
Galectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Cirrhosis
August 02, 2016 08:45 ET
|
Galectin Therapeutics
NORCROSS, Ga., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer,...
FibroGen Announces Receipt of $62 Million License Payment from AstraZeneca
July 08, 2016 04:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, July 08, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq:FGEN) (“FibroGen”), a research-based biopharmaceutical company, announced today that it has received a scheduled $62 million...
FibroGen Announces Fiscal 2015 Financial Results
February 29, 2016 16:02 ET
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 29, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) (“FibroGen”), a research-based biopharmaceutical company, today reported financial results for the year ended December...